Can a quicker infusion make fabry treatment less burdensome?
NCT ID NCT06019728
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether giving Fabrazyme, a lifelong enzyme replacement therapy for Fabry disease, at a faster infusion rate is safe and tolerable. Eight patients who had been on Fabrazyme without recent reactions participated. The goal was to see if shortening infusion time could reduce treatment burden without causing side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Fabrazyme (agalsidase beta)
- What this could lead to
- If successful, this could allow Fabry patients to receive their enzyme replacement therapy infusions more quickly, reducing time spent in clinic.
- What could go wrong
- This is a small, completed phase 4 study with only 8 participants, so results may not apply to all patients. Faster infusions could increase the risk of infusion-related reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FABRY'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University School of Medicine Site Number : 1005
Atlanta, Georgia, 30322-1007, United States
-
Infusion Associates Site Number : 1001
Grand Rapids, Michigan, 49525, United States
-
Lysosomal and Rare Disorders Research and Treatment Center, Inc Site Number : 1002
Fairfax, Virginia, 22030, United States
-
Metropolitan Hospital Center Site Number : 1004
New York, New York, 10021, United States
-
UCLA Medical Center Site Number : 1003
Santa Monica, California, 90404, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.